Mike Ross, PhD, is an experienced venture capitalist with more than 20 years serving in senior operating executive roles for leading biotechnology companies.
Dr. Ross has been a managing partner at SV Health Investors since 2002 and also serves as an investment advisor for the Dementia Discovery Fund. Prior to SV, he spent over a decade at Genentech, where he was the tenth employee. Dr. Ross served various roles including Vice President of Development and Vice President of Medicinal and Biomolecular Chemistry, while leading multiple projects to commercial success. Dr. Ross started Genentech’s protein engineering and small molecule discovery effort. He was also the Founding Chief Executive Officer of Arris Pharmaceutical, MetaXen, ExSAR, and CyThera (now Viacyte). Additionally, Dr. Ross was managing partner in Didyma, LLC, a biotechnology management consulting firm. He has served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova.
Dr. Ross earned his Bachelor of Arts from Dartmouth, his doctorate in chemistry from the California Institute of Technology, and focused his post-doctoral fellowship in molecular biology at Harvard.